

**Amendment of the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of claims:**

1. (Currently Amended) A process for extending lifespan of a mouse ~~[[i]]~~ or a human, ~~or a cell thereof~~ beyond a generic expected lifespan for said mouse ~~[[i]]~~ or said human, ~~or said cell thereof~~ comprising administering to said mouse ~~[[i]]~~ or said human, ~~or said cell thereof~~ a therapeutically effective amount of a composition comprising a C<sub>60</sub> compound or a combination of such C<sub>60</sub> compounds, said C<sub>60</sub> compounds being selected from the group consisting of *e,e,e* C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>2</sub>(CHCOOH), *e,e,e* C<sub>60</sub>(CHCOOH)<sub>3</sub>, C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>n</sub>, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C<sub>60</sub> moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C<sub>60</sub> moiety, wherein n = 1, 2, or 3, and wherein said mouse ~~[[i]]~~ or said human, ~~or said cell thereof~~ is not selected for a disability, thereby extending the lifespan of said mouse ~~[[i]]~~ or said human, ~~or said cell thereof~~ beyond the generic expected lifespan for said mouse ~~[[i]]~~ or said human, ~~or said cell thereof~~ by up to about 20%.

2. (Cancelled)

3. (Previously Presented) The process of Claim 1 wherein said at least one said C<sub>60</sub> compound is administered in a composition further comprising a pharmaceutically acceptable carrier.

4. (Previously Presented) The process of Claim 1 where n is 3.

5. (Previously Presented) The process of Claim 4 wherein said C<sub>60</sub> compound is *e,e,e* C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>3</sub>.

6. (Previously Presented) The process of Claim 1 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly, subcutaneously or orally.

7. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.

8. (Previously Presented) The process of Claim 7 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.

9. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered orally in an amount of at least 0.1 mg/kg.

10. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered orally in an amount of about 15 mg/kg.

11. (Previously Presented) The process of Claim 7 wherein said C<sub>60</sub> compound is administered daily.

12. (Previously Presented) The process of Claim 9 wherein said C<sub>60</sub> compound is administered daily.

13.-69. (Canceled)

70. (Currently Amended) The process as set forth in Claim 1 wherein an expected lifespan of said mouse [[;]] or said human ~~, or said cell thereof~~ prior to treatment is the generic expected lifespan for said mouse [[;]] or said human ~~, or said cell thereof~~.

71. (New) A process for extending lifespan of a mouse cell or a human cell, beyond a generic expected lifespan for said mouse cell or said human cell, comprising administering to said mouse cell or said human cell a therapeutically effective amount of a composition comprising a C<sub>60</sub> compound or a combination of such C<sub>60</sub> compounds, said C<sub>60</sub> compounds being selected from the group consisting of *e.e.e* C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>2</sub>(CHCOOH), *e.e.e* C<sub>60</sub>(CHCOOH)<sub>3</sub>, C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>n</sub>, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C<sub>60</sub> moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C<sub>60</sub> moiety, wherein n=1, 2, or 3, and wherein said mouse cell or said human cell is not selected for a disability, thereby extending the lifespan of said mouse cell or said human cell beyond the generic expected lifespan for said mouse cell or said human cell up to about 20%.

72. (New) The process as set forth in Claim 71 wherein an expected lifespan of said mouse cell or said human cell prior to treatment is the generic expected lifespan for said mouse cell or said human cell.